NUMINUS (NUMI.TO TSX) C$0.05 pre-market Jan 2026: earnings Jan 19 to watch
We note NUMI.TO stock trading at C$0.05 in pre-market on 14 Jan 2026 as the company prepares to report earnings on 19 Jan 2026. Volume has already risen to 989,752.00 shares, well above the 50-day average. Investors will watch top-line trends and cash flow after Numinus announced improved operating cash flow growth in FY 2024. This earnings spotlight frames short-term price risk and a possible catalyst for a volatile session when the company issues results and guidance.
NUMI.TO stock pre-market snapshot
The stock opens at C$0.05 with intraday range C$0.05–C$0.05 and market cap C$16,027,581.00. Trading volume of 989,752.00 shares shows a relative volume of 5.37, signaling heavier interest versus the average. Price momentum has improved year-to-date by 25.00%, while the one-year return remains -50.00%. We connect the jump in activity to the upcoming earnings announcement on 19 Jan 2026.
Earnings calendar and catalysts: NUMI.TO earnings and guidance
Numinus will report results on 19 Jan 2026, making short-term catalysts centered on revenue mix and margin commentary. Management commentary on Salvation Botanicals lab services and Numinus Health clinic utilization will be key. We expect analysts and traders to focus on cash flow metrics and any updated revenue guidance, given FY 2024 operating cash flow growth of 23.21% as reported.
Financials and valuation: NUMI.TO analysis
Numinus shows trailing EPS of -0.08 and a negative P/E near -0.63, reflecting losses and a small market cap. The company reports a current ratio of 0.61, cash per share of 0.00, and book value per share slightly negative. Revenue growth was 11.08% for FY 2024 while gross profit declined; operating income and net income grew, indicating narrowing losses but continued cash needs.
Technical and trading flow: NUMI.TO trading and liquidity
Technically, NUMI.TO sits near the 50-day average of C$0.05 and above the 200-day average of C$0.04, suggesting recent strength. Year high is C$0.13 and year low is C$0.03. Liquidity is thin but episodic; watch order size and bid-ask depth on earnings day, as small flows can move price materially given the share count of 320,551,620.00.
Meyka AI grade and short-term forecast
Meyka AI rates NUMI.TO with a score out of 100: 65.94, Grade B, suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a near-term reference target of C$0.08, implying 60.00% upside from the current C$0.05. Forecasts are model-based projections and not guarantees.
Risks and opportunities in the NUMI.TO outlook
Key risks include continued negative EPS, tight liquidity, and regulatory or reimbursement delays in psychedelic therapies. The balance sheet shows working capital pressure and a need for financing over time. Opportunities include rising clinic utilization, growth in lab services, and potential inclusion in thematic ETFs that track psychedelics, which can drive episodic demand source. Another comparator set and peer performance can be found on Investing.com source.
Final Thoughts
NUMI.TO stock trades at C$0.05 pre-market on 14 Jan 2026 with a clear near-term catalyst: the earnings report on 19 Jan 2026. The company has posted improving operating cash flow growth but remains loss-making with EPS -0.08 and a low current ratio of 0.61. Short-term traders should expect higher than normal volatility and monitor management comments on clinic utilization and lab services. Meyka AI’s forecast model projects a 12-month reference target of C$0.08, an implied upside of 60.00% from the current price. These model-based projections are not guarantees. We use Meyka AI as an AI-powered market analysis platform to frame price scenarios; this is not investment advice. Watch volume, guidance, and any capital-raising language in the report for the clearest signals on direction.
FAQs
What should investors watch in the NUMI.TO stock earnings report on Jan 19 2026?
Focus on revenue by division, clinic utilization, lab service margins, and cash flow. Any guidance on capital needs or expected clinic rollouts will likely move the share price.
Is NUMI.TO stock profitable and what are the key financial ratios?
Numinus is not profitable on a trailing basis with EPS -0.08 and a negative P/E. The current ratio is 0.61, and cash per share is minimal, indicating tight liquidity.
What is Meyka AI’s short-term forecast for NUMI.TO?
Meyka AI’s forecast model projects a reference target of C$0.08 versus the current C$0.05, implying roughly 60.00% upside. Forecasts are model-based projections and not guarantees.
How liquid is trading in NUMI.TO and how might earnings affect price?
Average volume is 184,378.00 but recent volume hit 989,752.00, so liquidity can spike. Earnings may trigger large moves because the market cap is small.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
